Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

Tirzepatide, the main ingredient in Mounjaro and Zepbound, is no longer in shortage, according to the U.S. Food and Drug Administration. Compounded copycat drugs containing tirzepatide, many sold ...

Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price ...

The FDA approved Zepbound (tirzepatide) as the first prescription ... In both trials, people taking either dose of Zepbound experienced a significant reduction in the number of apneas and ...

Anti-obesity medication: these are the surprising effects of taking Ozempic and Mounjaro - When Henry Conway hit his forties ...